866-997-4948(US-Canada Toll Free)

Malignant Glioma - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Dec 2013

Category :

Oncology

No. of Pages : 64 Pages


Global Markets Directs, \'Malignant Glioma Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Malignant Glioma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Malignant Glioma.
  • A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Malignant Glioma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Malignant Glioma Overview 7
Therapeutics Development 8
Pipeline Products for Malignant Glioma - Overview 8
Pipeline Products for Malignant Glioma - Comparative Analysis 9
Malignant Glioma - Therapeutics under Development by Companies 10
Malignant Glioma - Therapeutics under Investigation by Universities/Institutes 11
Malignant Glioma - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Malignant Glioma - Products under Development by Companies 16
Malignant Glioma - Products under Investigation by Universities/Institutes 17
Malignant Glioma - Companies Involved in Therapeutics Development 18
Sanofi 18
Cytomedix, Inc. 19
Stemline Therapeutics, Inc. 20
EirGen Pharma Ltd. 21
Tactical Therapeutics, Inc 22
Malignant Glioma - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Assessment by Therapeutic Class 34
Drug Profiles 36
Eir-060 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Dendritic Cell Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Dendritic Cell Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Carboxyamidotriazole Orotate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
SL-701 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Dendritic Cell Vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Dendritic Cell Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SAR-245409 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
WT1 Peptide Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
celecoxib + Dendritic Cell Vaccine + [temozolomide] + Radiation Therapy - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dendritic Cell Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Peptide Vaccine + [sargramostim] - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ALD-451 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
First Generation Attenuated Strain Of Reovirus - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Malignant Glioma - Recent Pipeline Updates 54
Malignant Glioma - Dormant Projects 56
Malignant Glioma - Discontinued Products 57
Malignant Glioma - Product Development Milestones 58
Featured News & Press Releases 58
Jul 01, 2013: Activartis Cancer Immunotherapy receives Orphan Drug Designation from FDA 58
Jun 14, 2013: Chugai Pharma Receives Japanese Approval For Additional Indication And Dosage And Administration Of Malignant Glioma For Avastin 59
May 28, 2013: DelMar Pharma To Present Clinical Trials Data For VAL-083 Brain Cancer Trial At ASCO Annual Meeting 60
Mar 25, 2013: SBI Pharmaceuticals Obtains Manufacture and Marketing Approval for Orally-administered in vivo Diagnostic Agent ALAGLIO for Malignant Glioma 60
Nov 19, 2012: Aeterna Zentaris Announces Positive Data From Phase I Trial Of Perifosine Combined With Temsirolimus In Malignant Glioma 61
May 27, 2010: Announcement of initiation of Phase III clinical study of orally active in vivo diagnostic agent for malignant glioma 62

Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Table


Number of Products under Development for Malignant Glioma, H2 2013 8
Number of Products under Development for Malignant Glioma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Late Stage Development, H2 2013 13
Comparative Analysis by Clinical Stage Development, H2 2013 14
Comparative Analysis by Early Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
Malignant Glioma - Pipeline by Sanofi, H2 2013 18
Malignant Glioma - Pipeline by Cytomedix, Inc., H2 2013 19
Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2013 20
Malignant Glioma - Pipeline by EirGen Pharma Ltd., H2 2013 21
Malignant Glioma - Pipeline by Tactical Therapeutics, Inc., H2 2013 22
Assessment by Monotherapy Products, H2 2013 23
Assessment by Combination Products, H2 2013 24
Number of Products by Stage and Target, H2 2013 27
Number of Products by Stage and Mechanism of Action, H2 2013 29
Number of Products by Stage and Route of Administration, H2 2013 31
Number of Products by Stage and Molecule Type, H2 2013 33
Number of Products by Stage and Therapeutic Class, H2 2013 35
Malignant Glioma Therapeutics - Recent Pipeline Updates, H2 2013 54
Malignant Glioma - Dormant Projects, H2 2013 56
Malignant Glioma - Discontinued Products, H2 2013 57

List of Chart


Number of Products under Development for Malignant Glioma, H2 2013 8
Number of Products under Development for Malignant Glioma - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 10
Number of Products under Investigation by Universities/Institutes, H2 2013 11
Comparative Analysis by Clinical Stage Development, H2 2013 14
Assessment by Monotherapy Products, H2 2013 23
Number of Products by Top 10 Target, H2 2013 25
Number of Products by Stage and Top 10 Target, H2 2013 26
Number of Products by Top 10 Mechanism of Action, H2 2013 28
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 29
Number of Products by Top 10 Route of Administration, H2 2013 30
Number of Products by Stage and Top 10 Route of Administration, H2 2013 31
Number of Products by Top 10 Molecule Type, H2 2013 32
Number of Products by Stage and Top 10 Molecule Type, H2 2013 33
Number of Products by Top 10 Therapeutic Class, H2 2013 34
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 35

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *